
WFH Educational: Treatment choice in an era of change | Virtual Summit 2020
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
Year: 2018
Language: English
Author(s): National Hemophilia Foundation, European Haemophilia Consortium, Medscape Education, World Federation of Hemophilia
Format: Interactive module
The second activity in the Clinical Advances in Gene Therapy for Hemophilia CME curriculum, Gene Therapy: Past, Present, and Future, is a round table video discussion of the evolution of gene therapy in hemophilia. Watch three experts reflect on the development, ongoing research, and current and future uses of gene therapy in hemophilia. A transcript of the discussion makes it easy for all learners to follow along, and presentation slides containing key messages and pivotal gene therapy clinical trial data enhance the learning experience. Click the View Resource button to access the activity through the Medscape site. There you will have to register, which is free and straightforward.
This activity is part of the Clinical Advances in Gene Therapy for Hemophilia CME curriculum developed by the WFH in collaboration with the National Hemophilia Foundation (NHF), the European Haemophilia Consortium (EHC), and Medscape Education. These five online activities provide introductory information on gene therapy in hemophilia. While clinicians can qualify for CME credits all learners can obtain a completion certificate, or explore the activity to enhance their knowledge of gene therapy in hemophilia.
View the other activities in this curriculum:
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel
In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing
In this session from the WFH 2020 Virtual Summit, Barbara Konkle, Alfonso Iorio & Catherine Lambert will discuss & highlight
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor
With regulatory approval of the first gene therapy product expected, there is an urgent need for a mechanism to collect